Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech Milestones and Database Updates for July 6, 2010

|Includes:Astex Pharmaceuticals, Inc. (ASTX), DRRX, ENDP, IPCI, MIPI, MYRX, UTHR

Below is a sample morning note to clients, which includes new catalysts/milestones added to our database, as well as companies and products that have new data.

Dear Sample Client,


ENDP: Submitted Complete Response to Fortesta 2009 CRL on July 1, 2010 (Class 2 Resubmission), expected FDA approval January 1, 2011; response contained re-analysis of the primary variable (testosterone levels) in the original pivotal study and plans for a post-approval "hand-wash" study.

SUPG: Eisai plans to submit Dacogen sNDA for elderly AML by March 31, 2011 (based on secondary endpoints, did not meet primary endpoint)


UTHR, MIPI, IPCI, DRRX, Picoplatin, MGCD265, mocetinostat, Azixa, MPC-3100

RESEARCH - BPAX, AVII, CORT, EXAS (ask about our rates)

Andrew Nava LLC provides equity research services for both institutional and retail healthcare investors. We focus on fundamental research of small- to mid-cap healthcare companies with the potential for significant market cap appreciation in the next 6-12 months. Our investment theses are based on event-driven catalysts and value-driven growth.

Institutional services include contract analyst work, generation of trading and investing ideas, and reports on companies within our coverage universe. Our extensive relationships with company management, analysts, KOLs and industry professionals provide the insight which drives our research. With the exception of institutional consulting and contract work, retail clients have access to the same information that our institutional clients do.

Our research is powered by our database. Information is derived exclusively from public sources and is useful for tracking clinical trial data and upcoming company milestones. As of June 2010, the database covers over 290 publicly-traded biotechnology and pharmaceutical companies, more than 1000 profiles of approved and development-stage drugs, devices and diagnostics, and 17 different catalyst types.

For more information, please visit

Disclosure: No positions